

The General Practice Guide to Autoimmune Diseases

Edited by Y. Shoenfeld and P. L. Meroni

ThermoFisher
S C I E N T I F I C

The General Practice Guide to Autoimmune Diseases

Edited by Y. Shoenfeld and P. L. Meroni



PABST SCIENCE PUBLISHERS
Lengerich, Berlin, Bremen, Miami,
Riga, Viernheim, Wien, Zagreb

Bibliographic information published by Deutsche Nationalbibliothek
The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulation and therefore free for general use.

The authors and the publisher of this volume have taken care that the information and recommendations contained herein are accurate and compatible with the standards generally accepted at the time of publication. Nevertheless, it is difficult to ensure that all the information given is entirely accurate for all circumstances. The publisher disclaims any liability, loss, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this volume.

© 2012 Pabst Science Publishers, 49525 Lengerich

<http://www.pabst-publishers.de>

Printing: MercedesDruck, Berlin

Typesetting: Hilmar Schlegel, Berlin

Cover: Agentur für zeitgemäße Kommunikation Kaner Thompson

www.kanerthompson.de

ISBN 978-3-89967-770-6

Undifferentiated connective tissue diseases (UCTD)

Falk Hiepe

1 Definition

UCTD is an oligosymptomatic connective tissue disease with a limited autoantibody repertoire that does not meet the classification criteria of any specific connective tissue disease such as systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), systemic sclerosis (SSc), autoimmune myositis or mixed connective tissue disease (MCTD). Only a minority of patients with UCTD will develop a defined connective tissue disease.

2 Epidemiology

Data regarding prevalence and incidence of UCTD are not available although Mosca et al noted that 20 %–52 % of patients in rheumatology clinics with a CTD may have UCTD. Mainly women suffer from this disease (female : male ratio is 20 : 1). The mean age at disease onset is 32 years (range 7–72 years).

3 Clinical manifestations

The course of the disease is mild. Each patient exhibits few clinical manifestations, mainly arthralgia (66 %), arthritis (32 %), Sicca symptoms (30 %), Raynaud's phenomenon (30 %), leukopenia (19 %), photosensitivity (17 %), anaemia (15 %), oral ulcerations (14 %) and alopecia (13 %). Severe organ manifestations e. g. of CNS or kidneys are uncommon. Most patients present manifestations similar to SLE, SSc or SS with a related ANA profile but do not meet the corresponding classification criteria.

4 Laboratory

Inflammatory parameters (ESR, gamma globulins) may be slightly or moderate increased. CRP levels are often normal. Anaemia, leukopenia and thrombocytopenia may occur. Some patients have low C3 and/or C4 levels.

Autoantibody profile: Antinuclear antibodies (ANA) detected by indirect immunofluorescence on HEp2 cells are positive in all patients. The ANA titre is usually low. Detailed analysis of the ANA antibodies usually identifies Anti-Ro/SSA, anti-La/SSB, anti-centromere or anti-U1-RNP antibodies. A patient will usually present with only one specificity of ANA antibody. Anti-dsDNA antibodies are rarely detectable. Some patients show ANA positivity without any specific antibodies able to be identified.

Table 1. Preliminary Classification Criteria for Undifferentiated Connective-Tissue Disease.

Inclusion Criteria	Clinical manifestations which may be considered specific to a defined CTD and are thus excluders of UCTD*	Laboratory markers which may be considered specific to a defined CTD and are thus excluders of UCTD*
1. Signs and symptoms suggestive of a CTD but not fulfilling the diagnostic or classification criteria for any of the defined CTDs** for at least 3 years***	Malar rash Subacute cutaneous lupus Discoid lupus Cutaneous sclerosis Heliotrope rash Gottron's papules	Anti-dsDNA Anti-Smith Anti-Scl70
2. Presence of antinuclear antibodies determined on two different occasions	Erosive arthritis	

* Applicable to patients at disease onset

** Using established classification criteria for PM/DM,CTD, SLE SSc, RA and SS (see relevant chapters)

*** If the disease duration is less than 3 years, patients may be defined as having an early UCTD.

Adapted from Mosca et al. and Doria et al.

5 Classification criteria

Preliminary classification criteria were proposed by Mosca et al in 1990.

1. Signs and symptoms suggestive of a connective tissue disease, but not sufficient to meet the criteria for a defined connective tissue disease,
2. Positive ANA,
3. Disease duration of at least 3 years. Patients with shorter disease duration (< 3 years) are considered as early UCTD. During these 3 years, some of the so-called “early UCTD” patients develop a defined connective tissue disease.

An amendment has since been suggested to avoid the misdiagnosis of transitory or early, defined CTD (Table 1).

Differential diagnosis: defined connective tissue disease (SLE, primary Sjögren's syndrome, SSc, dermatomyositis, polymyositis, MCTD, scleroderma/myositis overlap), ANA-positive rheumatoid arthritis.

Treatment: In accordance with the mild clinical manifestations, UCTD patients require symptomatic therapy and sometimes no treatment at all. The therapy includes NSAID, low-dose glucocorticoids and antimalarials. Immunosuppressive drugs are not indicated.

References

- [1] Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. *Clin Exp Rheumatol* 1999; 17: 615–20.
- [2] Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. *Best practice & research. Clin Rheumatol* 2007; 21: 1011–23.
- [3] Mosca M, Tani C, Neri C, et al. Undifferentiated connective tissue diseases (UCTD). *Autoimmun Rev* 2006; 6: 1–4.
- [4] Mosca M, Tani C, Talarico R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases. *Autoimmun Rev* 2011; 10: 256–8.
- [5] Vaz CC, Couto M, Medeiros D, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. *Clin Rheumatol* 2009; 28: 915–21.
- [6] Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? *J Rheumatol* 2005; 32: 213–5.